Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Ermenegildo Zegna NV
ZGN
DexCom
DXCM
Workday
WDAY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 2.70%54.21B | 4.58%13.66B | 1.22%13.65B | 1.99%14.33B | 3.13%12.57B | 7.79%52.79B | -0.96%13.06B | 0.15%13.48B | 4.72%14.06B | 36.97%12.19B |
Operating revenue | 2.16%50.39B | 3.38%12.62B | 0.88%12.73B | 1.69%13.4B | 2.82%11.65B | 7.69%49.32B | -1.48%12.21B | -0.48%12.61B | 4.97%13.18B | 38.43%11.33B |
Cost of revenue | 4.31%42.75B | 0.37%10.48B | 0.68%10.87B | 9.55%10.85B | 7.21%10.55B | 2.61%40.98B | 5.06%10.44B | 1.48%10.8B | -5.79%9.91B | 11.21%9.84B |
Gross profit | -2.92%11.47B | 21.29%3.19B | 3.42%2.78B | -16.08%3.48B | -13.96%2.02B | 30.68%11.81B | -19.32%2.63B | -4.85%2.69B | 42.75%4.15B | 4,505.88%2.35B |
Operating expense | 5.59%8.24B | 5.30%2.07B | 8.92%2.14B | 5.65%2.1B | 2.42%1.94B | 7.85%7.81B | 4.92%1.96B | 5.60%1.96B | 4.81%1.98B | 17.38%1.9B |
Selling and administrative expenses | 0.72%1.81B | 8.60%480M | 8.84%468M | -6.75%456M | -6.85%408M | -0.88%1.8B | -8.68%442M | -13.13%430M | -2.98%489M | 31.93%438M |
-Selling and marketing expense | 0.72%1.81B | 8.60%480M | 8.84%468M | -6.75%456M | -6.85%408M | -0.88%1.8B | -8.68%442M | -13.13%430M | -2.98%489M | 31.93%438M |
Other operating expenses | 7.04%6.43B | 4.34%1.59B | 8.95%1.67B | 9.70%1.64B | 5.21%1.54B | 10.77%6.01B | 9.68%1.52B | 12.41%1.53B | 7.63%1.5B | 13.62%1.46B |
Operating profit | -19.50%3.22B | 68.42%1.12B | -11.43%643M | -36.01%1.38B | -82.93%77M | 122.50%4.01B | -52.02%665M | -24.92%726M | 113.74%2.16B | 128.80%451M |
Net non-operating interest income expense | 5.66%-1.47B | 5.21%-364M | 1.63%-363M | 7.25%-358M | 8.67%-379M | 11.00%-1.55B | 9.22%-384M | 13.99%-369M | 12.07%-386M | 8.79%-415M |
Non-operating interest income | -20.81%468M | -21.48%106M | -30.36%117M | -20.99%128M | -5.60%118M | 173.61%591M | 23.85%135M | 140.00%168M | 458.62%162M | 1,462.50%125M |
Non-operating interest expense | -9.84%1.93B | -9.44%470M | -10.61%480M | -11.31%486M | -7.96%497M | 9.33%2.15B | -2.44%519M | 7.62%537M | 17.09%548M | 16.63%540M |
Other net income (expense) | 54.59%-604M | 115.66%39M | 48.81%-536M | 114.29%2M | -484.21%-111M | -1,107.58%-1.33B | -629.79%-249M | -972.50%-1.05B | -146.67%-14M | 70.77%-19M |
Special income (charges) | 37.18%-610M | 255.56%14M | 41.62%-554M | --0 | -438.46%-70M | -403.11%-971M | -125.00%-9M | -2,464.86%-949M | --0 | 91.72%-13M |
-Less:Restructuring and merger&acquisition | ---- | ---- | --0 | --0 | -38.10%13M | --23M | --2M | --0 | --0 | --21M |
-Less:Impairment of capital assets | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
-Less:Other special charges | ---- | ---- | -41.62%554M | ---- | 812.50%57M | 2,054.55%948M | 75.00%7M | 2,464.86%949M | ---- | -200.00%-8M |
Other non- operating income (expenses) | 101.67%6M | 110.42%25M | 118.37%18M | 114.29%2M | -583.33%-41M | -210.46%-359M | -570.59%-240M | -162.42%-98M | -156.00%-14M | -106.52%-6M |
Income before tax | 2.94%1.15B | 2,384.38%795M | 62.90%-256M | -41.69%1.03B | -2,529.41%-413M | 502.69%1.12B | -96.83%32M | -204.86%-690M | 192.37%1.76B | 100.81%17M |
Income tax | 3.01%308M | 1,476.92%205M | 26.21%-107M | -26.82%311M | -1,542.86%-101M | 406.78%299M | -93.72%13M | -182.86%-145M | 234.65%425M | 101.55%7M |
Net income | 2.92%846M | 3,005.26%590M | 72.66%-149M | -46.41%717M | -3,220.00%-312M | 547.24%822M | -97.63%19M | -212.84%-545M | 181.09%1.34B | 100.61%10M |
Net income continuous Operations | 2.92%846M | 3,005.26%590M | 72.66%-149M | -46.41%717M | -3,220.00%-312M | 547.24%822M | -97.63%19M | -212.84%-545M | 181.09%1.34B | 100.61%10M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 2.92%846M | 3,005.26%590M | 72.66%-149M | -46.41%717M | -3,220.00%-312M | 547.24%822M | -97.63%19M | -212.84%-545M | 181.09%1.34B | 100.61%10M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 2.92%846M | 3,005.26%590M | 72.66%-149M | -46.41%717M | -3,220.00%-312M | 547.24%822M | -97.63%19M | -212.84%-545M | 181.09%1.34B | 100.61%10M |
Basic earnings per share | 2.38%1.29 | 2,900.00%0.9 | 72.29%-0.23 | -46.83%1.09 | -2,500.00%-0.48 | 530.00%1.26 | -97.56%0.03 | -212.16%-0.83 | 180.82%2.05 | 100.79%0.02 |
Diluted earnings per share | 2.48%1.24 | 2,700.00%0.84 | 72.29%-0.23 | -46.28%1.01 | -2,500.00%-0.48 | 536.84%1.21 | -97.37%0.03 | -220.29%-0.83 | 176.47%1.88 | 100.79%0.02 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |